Alvin Luk is a biotech executive, neuroscientist and entrepreneur with more than three decades in global drug development. He is President & Chief Medical Officer (Group) and U.S. CEO of HanchorBio, a clinical-stage immunology and immuno-oncology company building Fc-based designer biologics, and co-founder and CEO of CRISPR gene-editing company HuidaGene Therapeutics. Across his career he has contributed to roughly two dozen approved products and more than 250 global regulatory submissions, including LUXTURNA, the first FDA-approved gene therapy. A 2025 TIME100 Health honoree, he wants to turn HanchorBio into the 'Genentech of Asia.'
Connie Lehman is a radiologist who spent three decades reading mammograms and decided the picture could tell a different story. As founder and CEO of Boston-based Clairity, she built the first FDA-authorized AI platform that reads a routine screening mammogram and estimates a woman's five-year risk of developing breast cancer, spotting tissue patterns invisible to the human eye. A Professor of Radiology at Harvard Medical School with more than 300 peer-reviewed publications, she left a celebrated academic career to commercialize the idea that imaging should predict cancer, not just find it. TIME named her to its 2026 TIME100 Health list and Forbes to its 50 Over 50: Innovation list.